Compare MATX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATX | GKOS |
|---|---|---|
| Founded | 1882 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.0B |
| IPO Year | 1994 | 2015 |
| Metric | MATX | GKOS |
|---|---|---|
| Price | $183.82 | $142.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $163.33 | $126.92 |
| AVG Volume (30 Days) | 196.4K | ★ 707.8K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.85 | N/A |
| Revenue | ★ $3,344,500,000.00 | $507,442,000.00 |
| Revenue This Year | $4.65 | $23.32 |
| Revenue Next Year | $4.31 | $27.43 |
| P/E Ratio | $97.04 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $86.97 | $73.16 |
| 52 Week High | $189.99 | $146.75 |
| Indicator | MATX | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 67.95 |
| Support Level | $157.33 | $80.14 |
| Resistance Level | $189.99 | $146.75 |
| Average True Range (ATR) | 6.57 | 6.16 |
| MACD | -0.04 | 0.55 |
| Stochastic Oscillator | 79.20 | 84.68 |
Matson Inc is engaged in providing ocean transportation and logistics services. The company has two reportable business segments: Ocean Transportation and Logistics. The Ocean Transportation segment provides ocean freight transportation services to the domestic non-contiguous economies of Hawaii, Alaska, California, Okinawa, and different islands in the South Pacific. The Logistics segment offers long-haul and regional highway trucking services, warehousing and distribution services, supply chain management, and freight forwarding services. The firm generates the majority of its revenue from the Ocean Transportation segment.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.